|Table of Contents|

Mass spectrometry analysis of VIPR1 interacting protein in hepatocellular carcinoma cells and construction of prognosis model of hepatocellular carcinoma

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 17
Page:
3176-3182
Research Field:
Publishing date:

Info

Title:
Mass spectrometry analysis of VIPR1 interacting protein in hepatocellular carcinoma cells and construction of prognosis model of hepatocellular carcinoma
Author(s):
WANG Xiaoyan1; 2; ZHANG Hao1; 2; GUO Zehao1; 2; MO Zhijing1; 2
1.School of Intelligent Medicine and Biotechnology,Guilin Medical University,Guangxi Guilin 541199,China;2.Key Laboratory of Biochemistry and Molecular Biology in Guangxi University,Guangxi Guilin 541199,China.
Keywords:
VIPR1; HCC; Co-IP; LC-MS; prognostic
PACS:
R735.7
DOI:
10.3969/j.issn.1672-4992.2023.17.007
Abstract:
Objective:To screen the interaction proteins and hub interaction proteins of vasoactive intestinal peptide receptor 1(VIPR1) in hepatocellular carcinoma(HCC),and construct prognostic models of HCC.Methods:The protein complexes bound to Flag labeled antibodies were screened by Co-immunoprecipitation(Co-IP) and verified by SDS-PAGE silver staining and Western blot.The protein complexes bound by Flag labeled antibodies were analyzed by liquid chromatograph-mass spectrometer(LC-MS) to obtain the interacting proteins of VIPR1.Bioinformatics software and The Cancer Genome Atlas project(TCGA) database were used to screen hub interacting proteins,perform enrichment analysis,and to construct a prognostic model of HCC.LIHC datas from International Cancer Genome Consortium(ICGC) database and GSE14520 dataset were used as external datas to verify the prediction accuracy of the model.Results:A total of 196 interacting proteins of VIPR1 were obtained,8 key modules including 104 hub interacting proteins were screened,which were closely related to cytoskeleton,ribosome function and cellular immunity.7 key proteins were obtained,and Lasso regression model of HCC prognosis were constructed,which was subsequently validated with acceptable accuracy and clinical applicability in predicting HCC prognosis in two external data sets.Conclusion:The interacting proteins of VIPR1 can promote the development of HCC,and the HCC prognostic model constructed by the key proteins has good accuracy.

References:

［1］SUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2021,71(3):209-249.
［2］CAO W,CHEN HD,YU YW,et al.Changing profiles of cancer burden worldwide and in China:a secondary analysis of the global cancer statistics 2020［J］.Chin Med J(Engl),2021,134(7):783-791.
［3］REUBI JC,LADERACH U,WASER B,et al.Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptor subtypes in human tumors and their tissues of origin［J］.Cancer Res,2000,60(11):3105-3112.
［4］ MOODY TW,GOZES I.Vasoactive intestinal peptide receptors:a molecular target in breast and lung cancer［J］.Curr Pharm Des,2007,3(11):1099-1104.
［5］ LIU SH,ZENG YJ,LI YH,et al.VPAC1 overexpression is associated with poor differentiation in colon cancer［J］.Tumour Biol,2014,35(7):6397-6404.
［6］ FERNANDEZ-MARTINEZ AB,CARMENA MJ,ARENAS MI,et al.Overexpression of vasoactive intestinal peptide receptors and cyclooxygenase-2 in human prostate cancer.Analysis of potential prognostic relevance［J］.Histol Histopathol,2012,27(8):1093-1101.
［7］ ZHAO LF,YU ZP,ZHAO BQ.Mechanism of VIPR1 gene regulating human lung adenocarcinoma H1299 cells［J］.Med Oncol,2019,36(11):91.
［8］ BALSTER DA,O'DORISIO MS,ALBERS AR,et al.Suppression of tumorigenicity in neuroblastoma cells by upregulation of human vasoactive intestinal peptide receptor type 1［J］.Regul Pept,2002,109(1-3):155-165.
［9］LIU GJ,WU DM,WEN YY,et al.Immune-associated molecular occurrence and prognosis predictor of hepatocellular carcinoma:an integrated analysis of GEO datasets［J］.Bioengineered,2021,12(1):5253-5265.
［10］XU BJ,LYU W,LI XY,et al.Prognostic genes of hepatocellular carcinoma based on gene coexpression network analysis［J］.J Cell Biochem,2019,120(7):11616-11623.
［11］LU SC,LU HM,JIN RZ,et al.Promoter methylation and H3K27 deacetylation regulate the transcription of VIPR1 in hepatocellular carcinoma［J］.Biochem Biophys Res Commun,2019,509(1):301-305.
［12］宁诗雨，何春梅，郭泽皓，等.VIPR1启动子甲基化促进转录因子AP-2α下调VIPR1的表达并促进肝细胞癌的生长［J］.南方医科大学学报,2022,42(7):957-965. NING SY,HE CM,GUO ZH,et al.VIPR1 promoter methlation promotes transcription factor AP-2α binding to inhibit VIPR1 expression and promote hepatocellular carcinoma cell growth in vitro［J］.J South Med Univ,2022,42(7):957-965.
［13］ZHAO LJ,CAO JZ,HU KX,et al.RNA-binding protein RPS3 contributes to hepatocarcinogenesis by post-transcriptionally up-regulating SIRT1［J］.Nucleic Acids Res,2019,47(4):2011-2028.
［14］MORIBE T,IIZUKA N,MIURA T,et al.Identification of novel aberrant methylation of BASP1 and SRD5A2 for early diagnosis of hepatocellular carcinoma by genome-wide search［J］.Int J Oncol,2008,33(5):949-958.
［15］HE HM,XIAO L,CHENG SN,et al.Annexin A2 enhances the progression of colorectal cancer and hepatocarcinoma via cytoskeleton structural rearrangements［J］.Microsc Microanal,2019,25(4):950-960.
［16］SALVI A,BONGARZONE I,FERRARI L,et al.Molecular characterization of LASP-1 expression reveals vimentin as its new partner in human hepatocellular carcinoma cells［J］.Int J Oncol,2015,46(5):1901-1912.
［17］HU L,LAU SH,TZANG CH,et al.Association of Vimentin overexpression and hepatocellular carcinoma metastasis［J］.Oncogene,2004,23(1):298-302.
［18］HOLMILA R,SKLIAS A,MULLER DC,et al.Targeted deep sequencing of plasma circulating cell-free DNA reveals Vimentin and Fibulin 1 as potential epigenetic biomarkers for hepatocellular carcinoma［J］.PLoS One,2017,12(3):e0174265.
［19］KITAMURA Y,SHIRAHATA A,SAKURABA K,et al.Aberrant methylation of the Vimentin gene in hepatocellular carcinoma［J］.Anticancer Res,2011,31(4):1289-1291.
［20］LIAO YN,SHAO ZL,LIU Y,et al.USP1-dependent RPS16 protein stability drives growth and metastasis of human hepatocellular carcinoma cells［J］.J Exp Clin Cancer Res,2021,40(1):201.
［21］ZHANG YY,ZHANG ZM.The history and advances in cancer immunotherapy:understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications［J］.Cell Mol Immunol,2020,17(8):807-821.
［22］ABDELRAHIM M,ESMAIL A,SAHARIA A,et al.Utilization of immunotherapy for the treatment of hepatocellular carcinoma in the peri-transplant setting:Transplant oncology view［J］.Cancers(Basel),2022,14(7):1760.
［23］REN SH,QIN YF,QIN H,et al.N6-methyladenine-related signature for immune microenvironment and response to immunotherapy in hepatocellular carcinoma［J］.Int J Gen Med,2022,15:3525-3540.
［24］YANG C,SHAO YD,WANG XJ,et al.The effect of the histone chaperones HSPA8 and DEK on tumor immunity in hepatocellular carcinoma［J］.Int J Mol Sci,2023,24(3):2653.
［25］JIANG KQ,DONG CY,YIN ZL,et al.Exosome-derived ENO1 regulates integrin α6β4 expression and promotes hepatocellular carcinoma growth and metastasis［J］.Cell Death Dis,2020,11(11):972.
［26］JIANG SS,WENG DS,WANG QJ,et al.Galectin-3 is associated with a poor prognosis in primary hepatocellular carcinoma［J］.J Transl Med,2014,12:273.
［27］SONG MJ,PAN QZ,YANG JY,et al.Galectin-3 favours tumour metastasis via the activation of β-catenin signalling in hepatocellular carcinoma［J］.Br J Cancer,2020,123(10):1521-1534.

Memo

Memo:
National Natural Science Foundation of China（No.32060159）;国家自然科学基金项目（编号：32060159）；广西壮族自治区科技厅自然科学基金项目（编号：2020GXNSFAA159110）；广西高校中青年教师科研基础能力提升项目（编号：2023KY0525）
Last Update: 2023-07-31